KR20100088749A - Composition for prevention and treatment of skin diseases containing cyanidin-3-o-(2"-xylosyl) glucoside - Google Patents

Abstract

PURPOSE: A pharmaceutical composition containing cyanidin-3-O-(2''-xylosyl) glucoside is provided to suppress COX-2 and the transcription factors such as AP-1 and NF-kappaB. CONSTITUTION: A pharmaceutical composition for preventing and treating dermatitis contains 0.1-50 weight% of Acanthopanax sessiliforium extract as an active ingredient. The Acanthopanax sessiliforium extract is obtained by drying Acanthopanax sessiliforium at 30-40°C for 44-52 hours, pulverizing, adding 50-99% of ethanol to the dried powder and extracting for 20-28 hours. The concentration of Acanthopanax sessiliforium is 10uM-1mM. The dermatitis includes skin cancer or skin inflammation.

Description

Composition for prevention and treatment of skin diseases containing cyanidin-3-3- (2 ”-xylosyl) glucoside}

The present invention relates to a pharmaceutical composition for preventing and treating skin diseases, and more particularly, cyanidin-3-O- (2 "-xyloxy) glucoside (cyanidin) contained in the Ogaza extract, which is a fruit of P. -3-O- (2 "-xylosyl) glucoside) relates to a pharmaceutical composition for preventing or treating skin diseases or a food composition for inhibiting skin diseases, characterized in that it comprises an active ingredient.

Recently, various diseases, including skin diseases, are rapidly increasing in modern people due to various external stimuli such as exposure to environmental pollution, increased stress, and changes in diet. Some of these external stimuli may cause disease by direct ingestion or contact, while others may not be readily recognizable, such as ultraviolet light, but are always exposed and inevitable.

Sun light is composed of visible light, ultraviolet light, and infrared light. Among them, ultraviolet light synthesizes vitamin D in the body and performs good functions such as sterilization, while the ozone layer is destroyed by environmental pollution and can be easily exposed. As long-term continuous exposure can lead to various skin diseases such as skin inflammation, skin aging, skin cancer. These ultraviolet rays are classified into A, B, and C according to their wavelengths, of which UVC is mostly blocked by the ozone layer, and UVA and UVB may cause skin diseases (Matsumura, Y. and Ananthaswamy, HN Expert). Rev Mol Med . 4 : 1-22, 2002; Afaq, F., Adhami, VM and Mukhtar, H. Mutat . Res . 571,153-73, 2005).

In particular, UVB (290-320 nm) can cause skin diseases with relatively low irradiance intensity, mainly causing sunburn, which causes erythema or blisters through inflammatory reactions, and can cause skin cancer if these irritation persists for a long time (Bode, AM and Dong, Z., SciSTKE . 2003; Matsumura, Y. and Ananthaswamy, HN Expert Rev Mol Med. 4 : 1-22, 2002).

On the other hand, Acanthopanax senticosus and A. sessiliflorus are Acanthopanax plants belonging to the family Araliaceae, with many branches branched near the roots and spreading in all directions.狀 複葉) and lobules are 3 ~ 5 ovate.

Pseudogapis include acanthosides A, B, C, D and chisanosides, polyacetylene, β- and glycan glycosides, including sesamine and savinin It is rich in cytosterol β-sitosterol), campesterol, vitamins and minerals. It is used as a supplement for mental and physical fatigue and weakness. It is also effective in treating hysteria, diabetes, atherosclerosis and rheumatoid myocarditis.

On the other hand, it is not disclosed about the skin disease prevention and treatment composition, which is characterized by containing the Ogaza extract, Ogaza fruit.

Therefore, the present invention is to include the organza extract or cyanidin-3-O- (2 "-xyloxy) glucoside (cyanidin-3-O- (2" -xylosyl) glucoside) which is the fruit of the thorn ogapi as an active ingredient It is an object of the present invention to provide a pharmaceutical composition for preventing and treating skin diseases or a food composition for inhibiting skin diseases.

In order to achieve the above object, the present invention adds 50-99% ethanol to the dried powder obtained by drying the fruit of the thorn oak skin at 30-40 ° C. for 44-52 hours at a ratio of 10-50 mL per 1 g of the dry powder. It provides a pharmaceutical composition for preventing or treating skin diseases or a food composition for inhibiting skin diseases, characterized in that the extract containing the organza extract obtained by extraction and filtration for 20 to 28 hours as an active ingredient.

In addition, the present invention is a skin disease prevention, characterized in that it contains cyanidin-3-O- (2 "-xyloxy) glucoside (cyanidin-3-O- (2" -xylosyl) glucoside) as an active ingredient And it provides a therapeutic pharmaceutical composition or a food composition for inhibiting skin diseases.

Hereinafter will be described in detail with respect to the problem solving means of the present invention.

Cyclooxygenase-2 (hereinafter referred to as "COX-2"), an enzyme involved in inflammatory reactions, is used to synthesize arachidonic acid present in cells into prostaglandins, an inflammatory substance. Representative enzymes produced (Hla T and Neilson K. Proc Natl Acad Sci USA . 89 (16): 7384-8, 1992, Grewe M et al., J Invest Dermatol . 101 (4): 528-31, 1993; Joyce E. Rundhaug et al., Mol Carcinog. , 46: 692-698, 2007).

On the other hand, various cancer-causing agents that cause cancer, such as ultraviolet radiation, cause oxidative stress, leading to cancer initiation and promotion. The biggest change in cells caused by this oxidative stress is the inhibition of GAP junction intercellular communication (GJIC). GJIC inhibition has been observed in many cancer cells, and this GJIC recovery ability is used as an indicator of cancer prevention and treatment.

The present invention is a pharmaceutical composition or a food composition for inhibiting skin disease, characterized in that it comprises an extract of the organza fruit, which is the fruit of thorn ogapi, as an active ingredient in order to prevent and treat skin diseases caused by the above causes. To provide.

"Includes as an active ingredient" means that the extract of the organza of the present invention to the pharmacological effect of preventing and inhibiting the skin disease, the organoza extract is added to the pharmaceutical composition for preventing and treating skin diseases For the drug delivery and stabilization, etc., various ingredients are added as subcomponents to be formulated in various forms.

Ogaza extract, which is the fruit of the ogapi contained as an active ingredient in the present invention, 50 ~ 99% ethanol in the dry powder obtained by grinding after drying the fruit of the thorny oak peel at 30 ~ 40 ℃ 44 ~ 52 hours 10 ~ per 1g dry powder The extract was prepared by adding 50 mL, followed by extraction and filtration for 20 to 28 hours, without destroying the active ingredients contained in organza.

The Ogaza extract obtained as described above was an extract containing the pigment component of Ogaza. In the following Experimental Example, it was referred to as 'pigmentation extract', and the 'pigmentation extract' was fractionated using 'Semipreparative HPLC' which can be collected at the same time. Thus, 'separated pigment extract' was obtained. The obtained, dye separation extract "was identified as" LC-ESI-MS chromatography, and the ^{'1 H', '13 C} , -NMR''cyanidin-3-O- (2 "-xylosyl) glucoside' through analysis .

The present invention is due to the pigment component of the organza in the organza extract, the promoter activity of COX-2 and its associated transcription factor, activator protein-1 ("AP-1"), nuclear factor-kappa B ( It was confirmed that the activity of Nuclear factor-kappa B, hereinafter "NF-kB") was inhibited, and the suppressed intercellular signaling was restored again.

On the other hand, the content of the organza extract contained in the pharmaceutical composition for preventing and treating skin diseases or the food composition for inhibiting skin diseases of the present invention is not limited to a specific range, but preferably contains 0.1 to 50% by weight. , The concentration of Ogaza extract is most preferably 10μM ~ 1mM.

On the other hand, for many patients, the standard dosage of the pharmaceutical composition for preventing and treating skin diseases of the present invention may be changed by the individual characteristics of the patient. Ideal dosages and dosing schedules for pharmaceutical compositions for the prevention and treatment of skin diseases can be determined, for example in terms of specific needs and the overall conditions of the patient, to determine the most appropriate treatment strategy. For the pharmaceutical compositions for preventing and treating skin diseases of the present invention, numerous references can be referred to in determining an appropriate dosage.

In addition, appropriate dosages of the pharmaceutical compositions for preventing and treating skin diseases of the present invention may be generally determined in vitro or in animal models. For example, the appropriate dosage may be determined by adding various concentrations of the pharmaceutical composition for preventing and treating skin diseases of the present invention to target cells in vitro.

On the other hand, in the pharmaceutical composition for the prevention and treatment of skin diseases of the present invention, the skin diseases are for example skin cancer and dermatitis. And the formulation of the pharmaceutical composition for preventing and treating skin diseases according to the present invention is not limited to a specific kind but preferably Warnings (PLASTERS), Granules (GRANULES), Lotions (LPTIONS), Linings (LINIMENTS), LIMONADES, AROMATIC WATERS, POWDERS, Syrups, SYRUPS, OPHTALMIC OINTMENTS, LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, ELIXIRS, OINTMENTS, FLUIDEXTRACTS, Emulsions, SUPESIONS, DECOCTIONS, INFUSIONS, OPHTHALMIC SOLUTIONS, TABLETS, Suppositories (SUPPOSITIORIES), INJECTIONS, INJECTIONS, SPIRITS, CATAPLSMA, CAPSULES, CREAMS, TROKES, TINCHES, PASTES ), Pills (PILLS), soft or hard gelatin capsules are any one selected from.

On the other hand, the present invention is used as a food composition for inhibiting skin diseases, but the food formulation is not limited to a specific one, but preferably meat, grains, caffeine drink, general beverage, chocolate, bread, snacks, confectionery, pizza, jelly Noodles, gums, ice creams, alcoholic beverages, alcohol, vitamin complexes and other health supplements are any one selected from.

The present invention provides cyanide-3-O- (2 "-xylyl) glucoside (cyanidin-3-O- (2" -xylosyl) glucoside) as an active ingredient, preventing and treating skin diseases. It provides a pharmaceutical composition or a food composition for inhibiting skin diseases.

"Included as an active ingredient" means the prevention and inhibition of skin diseases from cyanidin-3-O- (2 "-xylosyl) glucoside Cyanidin-3-O- (2 "-xylyl) glucoside (cyanidin-3-O- (2" -xylosyl) glucoside) in pharmaceutical composition for preventing and treating skin diseases Means to be added, including the addition of various components as a subcomponent for drug delivery and stabilization, etc., to be formulated in various forms (formulation).

Meanwhile, the pharmaceutical composition for preventing and treating skin diseases of the present invention or the food composition for inhibiting skin diseases is preferably cyanidin-3-O- (2 "-xyloxy) glucoside (cyanidin-3-O- (2"). -xylosyl) glucoside) is recommended to contain 1μM ~ 50mM.

On the other hand, for many patients, the standard dosage of the pharmaceutical composition for preventing and treating skin diseases of the present invention may be changed by the individual characteristics of the patient, and a substantially skilled clinician may use the skin of the present invention for the patient. Ideal dosages and dosing schedules for pharmaceutical compositions for the prevention and treatment of diseases can be determined, for example, in terms of specific needs and overall conditions of the patient, to determine the most appropriate treatment strategy. For the pharmaceutical compositions for preventing and treating skin diseases of the present invention, numerous references can be referred to in determining an appropriate dosage.

In addition, appropriate dosages of the pharmaceutical compositions for preventing and treating skin diseases of the present invention may be generally determined in vitro or in animal models. For example, the appropriate dosage may be determined by adding various concentrations of the pharmaceutical composition for preventing and treating skin diseases of the present invention to target cells in vitro.

On the other hand, in the pharmaceutical composition for the prevention and treatment of skin diseases of the present invention, the skin diseases are for example skin cancer and dermatitis. And the formulation of the pharmaceutical composition for preventing and treating skin diseases according to the present invention is not limited to a specific kind but preferably Warnings (PLASTERS), Granules (GRANULES), Lotions (LPTIONS), Linings (LINIMENTS), LIMONADES, AROMATIC WATERS, POWDERS, Syrups, SYRUPS, OPHTALMIC OINTMENTS, LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, ELIXIRS, OINTMENTS, FLUIDEXTRACTS, EMULSIONS, SUSPENSIONS, DECOCTIONS, INFUSIONS, OPHTHALMIC SOLUTIONS, TABLETS, Suppositories (SUPPOSITIORIES), INJECTIONS, INJECTIONS, SPIRITS, CATASLSMA, CAPSULES, CREAMS, TROCHES, TINCHES, PASTES ), Pills (PILLS), soft or hard gelatin capsules are any one selected from.

On the other hand, the present invention is used as a food composition for inhibiting skin diseases, but the food formulation is not limited to a specific one, but preferably meat, grains, caffeine drink, general beverage, chocolate, bread, snacks, confectionery, pizza, jelly Noodles, gums, ice creams, alcoholic beverages, alcohol, vitamin complexes and other health supplements are any one selected from.

As described above, the Ogaza extract contained as an active ingredient in the pharmaceutical composition for preventing and treating skin diseases of the present invention or the food composition for inhibiting skin diseases is COX-2 inhibitory and transcription factors related thereto due to the pigment component present in the extract. In addition to inhibitory effects on AP-1 and NF-kB, it also exerts a restoring effect of GAP junction intercellular communication (GJIC ") inhibited by oxidative stress.

In addition, the present invention can reduce the consumer's rejection of chemical components by containing a natural extract of Ogaza extract, it can effectively prevent and treat skin diseases.

Hereinafter, the configuration and operation of the present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited to the following examples, and includes modifications of equivalent technical spirit.

Example  1: Ogaza Extract Manufacturer

Prickly lychee fruit was dried at 35 ° C. for 48 hours, pulverized, 4,000 mL of 80% ethanol was added to 200 g of dried powder, and extracted for 24 hours, followed by filtration and residue was extracted twice. The obtained Ogaza extract was an extract containing the pigment component of Ogaza and was called 'crude pigment extract'.

The crude pigment extract was fractionated using 'Semipreparative HPLC' which can be collected simultaneously and separated to obtain a 'separated pigment extract'. The 'separated pigment extract' was obtained by 'LC-ESI-MS chromatography' and ' ¹ H'. ',' ¹³ C, -NMR 'was identified as' cyanidin-3-O- (2 "-xylosyl) glucoside (Fig. 1)'.

Experimental Example 1 Measurement of COX-2 Promoter Activity Inhibitory Effect of Organza Extract

Experimental Example 1 is the organoza extract obtained in Example 1, more specifically, crude pigment extract and isolated pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) COX-2 (cyclochloro) by UVB Luciferase assay was used to determine whether it inhibits the cytokinase-2 (Cyclooxygenase-2) promoter activity.

7.5 mg of penicillin in 5% fetal bovine serum (FBS) was added to cells stably inserted with COX-2 luciferase plasmid in JB 6 P + cells (ATCC), a rat skin epithelial cell. / L, 7.5 mg / L of streptomycin and 200 mg / ml of G418 were incubated in a 5% CO ₂ , 37 ° C. incubator (Forma Scientific Co., Marjetta, OH, USA) . Media compositions were all used by GIBCO BRL (Grand Island, NY, USA).

The crude pigment extract and the separated pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) were pretreated for 5 hours at 5 μM, 10 μM, 20 μM and 40 μM, respectively, and then irradiated with UVB 0.05J / cm ² for 6 hours. Intracellular luciferase was extracted using a lysis buffer (0.1 mol / L potassium phosphate buffer (pH 7.8), 1% Triton X-100.1 mmol / L DTT, 2 mmol / L EDTA) Luciferase activity was measured using a meter (Luminoskan Ascent; Thermo Electron).

As a result of measuring the inhibitory effect on the COX-2 promoter activity of the organza extract containing the pigment component of organza (FIG. 2), the promoter activity of COX-2 was increased in all cells treated with the crude pigment extract or the separated pigment extract of the organza It confirmed that it decreased compared with the treatment group.

From the above results, Ogaza extract not only exerts an anti-inflammatory effect by inhibiting COX-2 promoter activity associated with the inflammatory response, but also a pharmaceutical composition or a food composition for inhibiting skin diseases of the present invention containing the Ogaza extract The anti-inflammatory effect on the human body could also be deduced.

Experimental Example 2: Determination of Inhibitory Effects of Organza Extracts Increased by UVB on Transcription Factor AP-1 and NF-kB Activity

Experimental Example 2 is the transcription factor AP of the organza extract obtained in Example 1, more specifically, the crude pigment extract and the separated pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) of the organza were increased by UVB. Luciferase assay was used to measure the inhibition of the activity of -1 (Activator protein-2) and NF-kB (Nuclear factor-kappa B).

AP-1 (Activator protein-2) and NF-kB (Nuclear factor-kappa B; Nuclear factor-kappa B) are COX-2 (cyclooxygenase-2, which measured activity inhibition in Experimental Example 1). The transcription factor associated with the expression of cyclooxygenase-2).

5% fetal bovine serum (FBS) was used to stably insert AP-1 and NF-kB luciferase plasmids into JB 6 P + cells (ATCC), a rat skin epithelial cell. 5% CO ₂ , 37 ° C incubator using MEM medium containing E. penicillin 7.5mg / L, streptomycin 7.5mg / L and G418 200mg / ml (Forma Scientific Co., Marjetta, OH, USA) Incubated at.

After pretreatment of crude pigment extract and isolated pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) of organza for 5 h, 10 μM, 20 μM and 40 μM for 1 hour, UVB 0.05 J / cm ² The cells were incubated for 6 hours using a lysis buffer (0.1 mol / L potassium phosphate buffer (pH 7.8), 1% Triton X-100. 1 mmol / L DTT, 2 mmol / L EDTA), and the luciferase present in the cell was extracted. The activity of luciferase was measured using a luminometer (Luminoskan Ascent; Thermo Electron).

As a result of measuring the inhibitory effect on the transcription factors AP-1 (FIG. 3) and NF-kB (FIG. 4) increased by UVB of the organoza extract containing the pigment component of the organza, both the crude pigment and the separated pigment extract of the organza were significant. It was confirmed that inhibiting the activity of AP-1 and NF-kB activated by UVB.

From the above results, it could be inferred that the organoza extract could inhibit the expression of COX-2, an enzyme involved in the inflammatory response by inhibiting the transcription factors AP-1 and NF-kB, and from which the organoza extract was contained. The anti-inflammatory effect of the pharmaceutical composition for preventing and treating skin diseases of the present invention or the food composition for inhibiting skin diseases could also be deduced.

Experimental Example 3: Effect of Ogaza Extract on Intercellular Signal Transduction

Experimental Example 3 has the effect of the organza extract obtained in Example 1, more specifically, the crude pigment extract and the separated pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) of the organza on intercellular signal transduction In order to determine the intercellular signaling recovery capacity was measured.

Rat liver epithelial cells in WB-F344 (treatment available: KE Dr. Trosko, Michigan State University) with 10% FBS (fetal bovine serum: FBS) 5 % by using the D-medium medium which is containing CO _2, The cells were cultured in a 37 ° C. incubator (Forma Scientific Co., Marjetta, OH, USA).

100 mM of hydrogen peroxide was used to inhibit intercellular signal transmission, followed by 5 μM, 10 μM, 20 μM, 40 μM of crude pigment extract and isolated pigment extract (cyanidin-3-O- (2 ”-xylosyl) glucosid) of organza 1 Treatment for time was confirmed the intercellular signaling recovery capacity of the Ogaza extract.

As a result of measuring the intercellular signal transduction recovery ability of the Ogaza extract containing the pigment component of the organza (Fig. 5), it was confirmed that the intracellular signal suppressed by hydrogen peroxide was recovered by the crude pigment and the separated pigment extract of the organza have.

From the above results, it was confirmed that the Ogaza extract can restore the suppressed intercellular signaling, and from there, the intercellular signal of the pharmaceutical composition for preventing and treating skin diseases or the food composition for inhibiting skin diseases, which contains the Ogaza extract. It was possible to infer the recovery recovery ability.

Figure 1 is obtained by separating the obtained crude pigment extract using 'Semipreparative HPLC' which can be collected at the same time, the 'separated pigment extract' obtained, the 'separated pigment extract' obtained 'LC-ESI-MS chromatography'^'1H', a block diagram for a ^'13 C, -NMR' a 'cyanidin-3-O- (2 "-xylosyl) glucoside' identified through the analysis.

Figure 2 is a diagram showing the inhibitory effect on the COX-2 promoter activity of crude pigment extract, isolated pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) of the organza. 2 is UVB irradiated group, lane 3 is UVB and organochromic pigment extract 5 μg / ml treatment group, lane 4 is UVB and organo crude pigment extract 10 μg / ml treated group, lane 5 is UVB and organo crude pigment extract 20 μg / ml ml treatment group, lane 6 is UVB and organochromic pigment extract 40 μg / ml treatment group, lane 7 is the organoisolate pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) 5 μg / ml treatment group, lane 8 is the organo separate pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) 10 μg / ml treatment group, lane 9 is the organiza separated pigment extract (cyanidin-3-O- (2" -xylosyl) glucosid) 20 μg / ml treatment group, lane 10 is a 40 μg / ml treatment group of organo separate separation pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid).

Figures 3 and 4 show the inhibitory effect of the activity of AP-1 and NF-kB activated by UVB of crude pigment extract and isolated pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) of organza Lane 1 is an untreated control group, lane 2 is a UVB irradiated group, lane 3 is a UVB and organochromic pigment extract 5 μg / ml treatment group, lane 4 is a UVB and organo crude pigment extract 10 μg / ml treated group, lane 5 is 20 μg / ml of UVB and organo crude pigment extract, lane 6 is 40 μg / ml of UVB and organo crude pigment extract, and lane 7 is organo separate pigment extract (cyanidin-3-O- (2 "-xylosyl). ) glucosid) 5 μg / ml treatment group, lane 8 is organoza separate pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) 10 μg / ml treatment group, lane 9 is organoza separation pigment extract (cyanidin-3 -O- (2 "-xylosyl) glucosid) 20μg / ml treatment group, lane 10 is a 40 μg / ml treatment group of the Ogaza separation pigment extract (cyanidin-3-O- (2" -xylosyl) glucosid).

Figure 5 is a diagram showing the effect of restoring the intercellular signaling of the crude pigment extract, isolated pigment extract (cyanidin-3-O- (2 "-xylosyl) glucosid) of the organza inhibited by treatment with hydrogen peroxide. Control group, lane 2 is 100 mM hydrogen peroxide treatment group, lane 3 is 100 mM hydrogen peroxide and 100 mg / ml Ogaza crude pigment extract, lane 4 is hydrogen peroxide and organo separate pigment extract (cyanidin-3-O- (2 "-xylosyl glucosid) 100 mg / ml.

Claims (18)

50 ~ 99% ethanol was added at a rate of 10-50 mL per 1g of dry powder, and then extracted and filtered for 20 ~ 28 hours. A pharmaceutical composition for preventing and treating skin diseases, comprising the obtained Ogaza extract as an active ingredient. The method of claim 1, Pharmaceutical composition for preventing and treating skin diseases, Pharmaceutical composition for preventing and treating skin diseases, characterized in that containing 0.1 to 50% by weight of Ogaza extract. The method of claim 2, Organza extract, A pharmaceutical composition for preventing and treating skin diseases, wherein the concentration is 10 μM to 1 mM. The method of claim 1, Skin disease, Pharmaceutical composition for preventing and treating skin diseases, characterized in that the skin cancer. The method according to claim 1, Skin disease, Pharmaceutical composition for the prevention and treatment of skin diseases, characterized in that the dermatitis. The method of claim 1, The composition, PLASTERS, Granules, Lotions, LPTIONS, LINIMENTS, LIMONADES, AROMATIC WATERS, POWDERS, Syrups, SYRUPS (OPHTALMIC OINTMENTS), LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, ELIXIRS, OINTMENTS, FLUIDEXTRACTS, Emulsions, Emulsions SUSPESIONS, DECOCTIONS, INFUSIONS, OPTHALMIC SOLUTIONS, TABLETS, suppositories, SUPOSITIORIES, INJECTIONS, SPIRITS, CATAPLSMA, CAPSULES (CAPSULES) ), Creams (CREAMS), troches (TROCHES), tinks (TINCTURES), pasta (PASTES), pills (PILLS), soft or hard gelatin capsules, characterized in that any one of the skin disease prevention And pharmaceutical compositions for treatment. 50 ~ 99% ethanol was added at a rate of 10-50 mL per 1g of dry powder, and then extracted and filtered for 20 ~ 28 hours. A food composition for inhibiting skin diseases, comprising the obtained Ogaza extract as an active ingredient. According to claim 7, Food composition for skin disease suppression, Food composition for inhibiting skin diseases, characterized in that containing 0.1 to 50% by weight of Ogaza extract. The method of claim 8, Organza extract, A food composition for inhibiting skin diseases, wherein the concentration is 10 μM to 1 mM. The method of claim 7, wherein Food, Meat, cereals, caffeine drinks, general beverages, chocolate, bread, snacks, confectionery, pizza, jelly, noodles, gum, ice cream, alcoholic beverages, alcohol, vitamin complexes and other health supplements A food composition for inhibiting skin diseases. Pharmaceutical composition for the prevention and treatment of skin diseases, comprising cyanidin-3-O- (2 "-xylyl) glucoside (cyanidin-3-O- (2" -xylosyl) glucoside) as an active ingredient . The method of claim 11, Pharmaceutical composition for preventing and treating skin diseases, Cyanidin-3-O- (2 "-xylyl) glucoside (cyanidin-3-O- (2" -xylosyl) glucoside) containing 1μM ~ 50mM pharmaceutical composition for preventing and treating skin diseases . The method of claim 11, Skin disease, Pharmaceutical composition for preventing and treating skin diseases, characterized in that the skin cancer. The method of claim 11, Skin disease, Pharmaceutical composition for the prevention and treatment of skin diseases, characterized in that the dermatitis. The method of claim 11, The composition, PLASTERS, Granules, Lotions, LPTIONS, LINIMENTS, LIMONADES, AROMATIC WATERS, POWDERS, Syrups, SYRUPS (OPHTALMIC OINTMENTS), LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, ELIXIRS, OINTMENTS, FLUIDEXTRACTS, Emulsions, Emulsions SUSPESIONS, DECOCTIONS, INFUSIONS, OPTHALMIC SOLUTIONS, TABLETS, suppositories, SUPOSITIORIES, INJECTIONS, SPIRITS, CATAPLSMA, CAPSULES (CAPSULES) ), Creams (CREAMS), troches (TROCHES), tinctures (TINCTURES), pasta (PASTES), pills (PILLS), soft or hard gelatin capsules characterized in that any one selected from Therapeutic pharmaceutical composition. Cyanidin-3-O- (2 "-xylyl) glucoside (cyanidin-3-O- (2" -xylosyl) glucoside) as an active ingredient, characterized in that the food composition for inhibiting skin diseases. The method of claim 16, Food composition for skin disease suppression, A cyanide-3-O- (2 "-xylyl) glucoside (cyanidin-3-O- (2" -xylosyl) glucoside) containing 1 μM to 50 mM, a food composition for inhibiting skin diseases. The method of claim 16, Food, Meat, cereals, caffeine drinks, general beverages, chocolate, bread, snacks, confectionery, pizza, jelly, noodles, gum, ice cream, alcoholic beverages, alcohol, vitamin complexes and other health supplements A food composition for inhibiting skin diseases.

Images